Software engineers straight out of college often make six-figure salaries, not counting equity compensation.Technologyread more
Representatives from the Chinese side say they think it likely that Chinese President Xi Jinping will attend the G-20 meeting later this month. But in order to reach a trade...China Economyread more
Wall Street, though, is clamoring for a rate cut, with an 85% chance of a move in July and a 61% probability of three reductions by year's end.The Fedread more
A company spokesperson said the outage was the result of a "an internal technology issue" and was not security related.Retailread more
Using MIT's living wage calculator, CNBC Make It mapped out the minimum amount a single parent must earn to meet their basic needs without relying on outside help in every...Earnread more
The flattening of the yield curve is exuding a bad omen for the stock market if history is any guide.Marketsread more
Stratolaunch, the world's largest airplane, which flew once, is up for sale, sources familiar told CNBC.Investing in Spaceread more
Transparency is key… or is it? With the first-ever non-transparent, actively managed exchange-traded fund receiving approval from the SEC, "ETF Edge" goes straight to the...ETF Edgeread more
Mired in a crisis over its best-selling 737 Max plane, Boeing could hand the spotlight over to its rival Airbus at the Paris Air Show.Airlinesread more
A new update to the Apple Watch called watchOS 6 will notify you if the environment you're in is too loud and could damage your hearing.Technologyread more
Flood waters receded in portions of the nation's Midwest in the past week, but the weather forecast calls for heavy rain and severe thunderstorms over the next few days that...Agricultureread more
Although Jefferies is concerned about the pharmaceutical industry's prospects, the firm's analyst said there are several drug companies that can outperform the market.
"The sector has had a decent performance in 2017, as concerns over US drug pricing have waned," analyst Jeffrey Holford wrote in a note to clients Monday. "Whilst the sector has acted better recently, we still see significant challenges ahead," including competition, pricing and similar drugs made by rival companies.
The is up 11 percent year-to-date through Friday compared to the S&P 500's 12 percent gain.
Here are three buy-rated companies in the industry recommended by Jefferies as stocks that can still do well, along with the firm's current price targets.